Myo-Inositol

The one-paragraph version

Inositol is a naturally occurring sugar-alcohol your body and diet already supply; myo-inositol is the main form, sometimes paired with D-chiro-inositol (DCI) in a 40:1 ratio meant to mimic the body's plasma balance S1. In women with PCOS, randomized trials suggest it can improve some insulin-resistance and hormonal markers, which is why it shows up in the PCOS conversation S1S2S3. But the 2023 update of the International Evidence-based PCOS Guidelines reviewed the trials and concluded the evidence is limited and inconclusive, with an average trial arm of roughly three dozen people and high variability S1. For gestational-diabetes risk it "may" help but the certainty is low S4, and for anxiety or mood the picture is weak and contradictory S5S6. Net: a low-risk adjunct worth discussing with a clinician if you have PCOS or a metabolic reason, not a proven fix and not a general wellness must-have.

What it is and how it works

Myo-inositol is a six-carbon sugar alcohol (a "pseudo-vitamin," once loosely called vitamin B8) found in foods like grains, beans, nuts, and fruit, and also made by the body S1S5. It acts as a precursor to intracellular second messengers involved in insulin signaling; D-chiro-inositol is a related isomer with a distinct role, and the two exist in tissue-specific ratios S1. The proposed mechanism in PCOS is that supplementing inositol supports insulin signaling, which in turn may nudge the downstream hormonal picture (androgens, ovulatory markers) that insulin resistance can drive S1S2. This is a plausible structure-function story, not proof that inositol corrects the underlying condition S1.

What the evidence actually supports

• PCOS metabolic markers: Meta-analyses of RCTs report improvements in insulin-resistance measures (e.g., fasting insulin / HOMA-IR) and some hormonal markers with myo-inositol S2S3. The 2023 guideline review agrees there may be benefit "for some metabolic measures," with a possible ovulation signal noted particularly for D-chiro-inositol S1.
• Evidence quality is the honest headline: The guideline systematic review pooled ~30 trials (19 in meta-analyses), with arm sizes ranging from 8 to 195 and a mean of about 36 participants, high heterogeneity, and integrity concerns in some studies — leading to the conclusion that the evidence is "limited and inconclusive" S1. An umbrella review of the meta-analyses reaches a similarly cautious read S3.
• Versus metformin: Head-to-head data suggest broadly comparable reproductive outcomes, with metformin favored for some measures (waist-hip ratio, hirsutism) and inositol causing fewer GI side effects S1.
• Gestational-diabetes risk: A 2023 Cochrane review (7 RCTs, ~1,319 women) found myo-inositol may reduce gestational diabetes incidence, but certainty was low to very low and most trials were small and single-region — not enough to support a firm recommendation S4.
• Anxiety / mood: Early small crossover trials in panic disorder looked promising (inositol comparable to an SSRI in one study), but the overall base is scarce and a meta-analysis found no clear antidepressant or anti-anxiety effect; routine psychiatric use "cannot be recommended yet" S5S6.

Who actually benefits

The people with a real, evidence-based reason to consider it are those working with a clinician on PCOS-related or insulin-resistance markers — that is where the signal is most consistent, even if modest S1S2S3. People at higher risk of gestational diabetes sometimes discuss it with their obstetric team, but the evidence is only low-certainty and this is firmly a talk-to-your-clinician situation, not a self-start one S4. For the general population looking to it for anxiety, mood, or weight loss, the case is weak-to-absent S5S6. It will not "treat" or "cure" PCOS or any condition — at best it may move some markers as part of broader care S1.

Dosing (standard, well-established)

This describes what trials used; it is not a prescription. Confirm any regimen with your clinician, especially in pregnancy.

• PCOS trials commonly used myo-inositol in the range of roughly 1.2–4 g per day, frequently split into two doses S1. A widely studied formulation delivers myo-inositol with a small amount of D-chiro-inositol in a 40:1 ratio (for example ~550 mg MI + ~13.8 mg DCI taken twice daily), a ratio chosen to approximate the body's plasma balance S1.
• Gestational-diabetes-prevention trials typically studied myo-inositol around 2 g twice daily (≈4 g/day) begun in early-to-mid pregnancy — under clinical supervision S4.
• Psychiatric trials used much higher amounts (on the order of 12–18 g/day), which is well above general supplement use and produced inconsistent results S5S6.
• Benefits in trials generally required sustained use over weeks to months, not a single dose S1S2.

Safety

The marketing myths

• "Myo-inositol treats PCOS." No. Trials show effects on some markers, and the leading guideline still calls the evidence limited and inconclusive; it is an adjunct to discuss, not a treatment or cure S1.
• "The 40:1 ratio is clinically proven to be best." The ratio is designed to mirror plasma physiology and is heavily marketed, but whether it beats plain myo-inositol is still an open question, not settled science S1.
• "It's a natural anti-anxiety / antidepressant." Small early panic-disorder studies were encouraging, but pooled evidence shows no clear effect and experts say it can't be recommended for psychiatric use yet S5S6.
• "It's a weight-loss supplement." There is no good evidence for inositol as a standalone fat-loss aid; any metabolic effects are marker-level and context-specific S1S3.
• "More is better." Higher (psychiatric-range) doses mainly add GI side effects without reliably better results in the metabolic setting S1S5.

Sources are listed in the frontmatter (S1–S6). This guide describes evidence and regulatory/structure-function context only; it does not diagnose, treat, or recommend therapy for any condition.

Sources

Every reference below is a primary source cited in this guide.